查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587218

凝血因子集中市场：按凝血因子类型、产品剂型、应用和最终用户划分 - 2025-2030 年全球预测

Coagulation Factor Concentrates Market by Type of Coagulation Factor (Factor IX concentrates, Factor VII concentrates, Factor VIII concentrates), Product Formulation, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年凝血因子浓缩物市值为86.6亿美元，预计到2024年将达到88.4亿美元，复合年增长率为7.46%，预计到2030年将达到143.4亿美元。

凝血因子浓缩物在治疗出血性疾病（例如A型血友病、冯维勒布兰德病和其他凝血障碍）方面发挥重要作用。这些浓缩物是特定凝血因子的精製版本，用于补偿患者凝血因子缺乏或功能障碍。对凝血因子浓缩物的需求源于对有效且有针对性的治疗策略的需求，以控制出血事件并预防凝血病的长期併发症。其主要用途包括预防性治疗、按需治疗以及受影响患者的手术全期管理。主要最终使用者是医院、专科诊所和居家医疗机构。市场成长的推动因素包括出血性疾病意识的提高、生物技术的进步、医疗保健的改善以及血友病患病率的上升。重组 DNA 技术的创新、长效浓缩物的开发以及基因疗法是该领域的一些最新机会。鼓励公司专注于非因子疗法的研究和开发以及改进的给药方法，以巩固其在这个快速成长的市场中的地位。然而，治疗成本上升、替代治疗方法的可用性、严格的监管核准以及新兴市场的低认知度等挑战可能会阻碍市场成长。该市场中未满足的领域包括个人化医疗和开拓副作用较少的治疗方法。此外，采用数位健康工具进行有效的疾病管理可能代表着一条巨大的成长道路。凝血因子浓缩物市场的特点是激烈的竞争和不断的创新，以满足患者和医疗保健提供者的微妙需求。推动成长的关键研究领域包括探索新的分子标靶、提高生产过程的永续性以及透过创新的交付平台和教育倡议提高患者的依从性。

主要市场统计
基准年[2023] 86.6亿美元
预测年份 [2024] 88.4亿美元
预测年份 [2030] 143.4亿美元
复合年增长率（%） 7.46%

市场动态：针对快速发展的凝血因子浓缩物市场揭示的关键市场见解

供需的动态交互作用正在改变凝血因子浓缩物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 血友病和凝血障碍的盛行率
    • 加强生物技术研究与开发，开发有效的凝血因子浓缩物
    • 倾向于疾病的早期诊断和治疗
  • 市场限制因素
    • 与凝血因子浓缩物合成相关的污染问题
  • 市场机会
    • 改良凝血因子浓缩物简介
    • 基因治疗取得重大进展
  • 市场挑战
    • 严格的产品核可监管程序

波特五力：驾驭凝血因子浓缩物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对凝血因子浓缩物市场的影响

外部宏观环境因素在塑造凝血因子浓缩物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解凝血因子浓缩物市场的竞争状况

对凝血因子浓缩物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵凝血因子浓缩物市场供应商的绩效评估

FPNV定位矩阵是评估凝血因子浓缩物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了凝血因子浓缩物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对凝血因子浓缩物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 血友病和凝血缺陷的盛行率
      • 加强生物技术研究与开发，开发有效的凝血因子浓缩物
      • 疾病的早​​期诊断和治疗趋势
    • 抑制因素
      • 与凝血因子浓缩物合成相关的污染问题
    • 机会
      • 改良凝血因子浓缩物介绍
      • 基因治疗的重大进展
    • 任务
      • 严格的产品核可监管程序
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依凝血因子类型分類的凝血因子浓缩物市场

  • IX 因子 (FIX) 浓缩物
  • 因子 VII (FVII) 浓缩物
  • 因子 VIII (FVIII) 浓缩物
  • XIII 因子 (FXIII) 浓缩物

第七章 凝血因子浓缩物市场（依产品配方）

  • 血浆源性凝血因子浓缩物
  • 重组凝血因子浓缩物

第八章凝血因子集中市场：依应用分类

  • 血友病治疗
  • 外科手术

第九章凝血因子浓缩物市场：依最终使用者分类

  • 家庭护理设置
  • 医院
  • 专科诊所

第十章美洲凝血因子浓缩物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太凝血因子浓缩物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲凝血因子浓缩物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bayer AG
  • Bio Products Laboratory Limited
  • BIOGEN INC.
  • Biotest AG.
  • Cerus Corporation
  • Emergent BioSolutions Inc.
  • Kedrion SpA
  • LFB USA
  • Medscape Network
  • Novo Nordisk A/S
  • Octapharma USA, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-DD0700E81E59

The Coagulation Factor Concentrates Market was valued at USD 8.66 billion in 2023, expected to reach USD 8.84 billion in 2024, and is projected to grow at a CAGR of 7.46%, to USD 14.34 billion by 2030.

Coagulation factor concentrates play a critical role in the management of bleeding disorders such as hemophilia A and B, von Willebrand disease, and other coagulation deficiencies. These concentrates are purified preparations of specific coagulation factors used to replace or support deficient or dysfunctional clotting factors in patients. The necessity for coagulation factor concentrates stems from the need for effective and targeted treatment strategies to manage bleeding episodes and prevent long-term complications of coagulation disorders. Their primary applications include prophylactic treatment, on-demand therapy, and perioperative management in affected individuals. The primary end-users comprise hospitals, specialty clinics, and home care settings. Market growth is significantly driven by increased awareness of bleeding disorders, advancements in biotechnology, improved healthcare access, and the rising prevalence of hemophilia. Innovations in recombinant DNA technology, the development of long-acting concentrates, and gene therapy are some of the latest opportunities in this field. Companies are recommended to focus on R&D for non-factor therapies and enhanced delivery methods to solidify their positions in this burgeoning market. However, challenges such as high cost of therapies, availability of alternative treatments, stringent regulatory approvals, and limited awareness in developing regions can impede market growth. Unaddressed areas in the market include personalized medicine and the development of therapies with fewer side effects. Moreover, embracing digital health tools for effective disease management can present substantial growth avenues. The coagulation factor concentrates market is characterized by robust competition and a constant push for innovation to meet the nuanced demands of patients and healthcare providers. Key research areas for driving growth include exploring novel molecular targets, improving the sustainability of production processes, and enhancing patient adherence through innovative delivery platforms and educational initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 8.66 billion
Estimated Year [2024] USD 8.84 billion
Forecast Year [2030] USD 14.34 billion
CAGR (%) 7.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Coagulation Factor Concentrates Market

The Coagulation Factor Concentrates Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of hemophilia and clotting deficiencies
    • Increase in biotechnology R&D to develop effective coagulation factor concentrates
    • Inclination toward early diagnosis and treatment of diseases
  • Market Restraints
    • Contamination issues associated with the synthesis of coagulation factor concentrate
  • Market Opportunities
    • Introduction of improved coagulation factor concentrates
    • Significant advancements in gene therapy
  • Market Challenges
    • Stringent regulatory procedure for product approval

Porter's Five Forces: A Strategic Tool for Navigating the Coagulation Factor Concentrates Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Coagulation Factor Concentrates Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Coagulation Factor Concentrates Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Coagulation Factor Concentrates Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Coagulation Factor Concentrates Market

A detailed market share analysis in the Coagulation Factor Concentrates Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Coagulation Factor Concentrates Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Coagulation Factor Concentrates Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Coagulation Factor Concentrates Market

A strategic analysis of the Coagulation Factor Concentrates Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Coagulation Factor Concentrates Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Bio Products Laboratory Limited, BIOGEN INC., Biotest AG., Cerus Corporation, Emergent BioSolutions Inc., Kedrion S.p.A, LFB USA, Medscape Network, Novo Nordisk A/S, Octapharma USA, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Coagulation Factor Concentrates Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type of Coagulation Factor, market is studied across Factor IX (FIX) concentrates, Factor VII (FVII) concentrates, Factor VIII (FVIII) concentrates, and Factor XIII (FXIII) concentrates.
  • Based on Product Formulation, market is studied across Plasma-Derived Coagulation Factor Concentrates and Recombinant Coagulation Factor Concentrates.
  • Based on Application, market is studied across Hemophilia Treatment and Surgical Procedures.
  • Based on End-User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of hemophilia and clotting deficiencies
      • 5.1.1.2. Increase in biotechnology R&D to develop effective coagulation factor concentrates
      • 5.1.1.3. Inclination toward early diagnosis and treatment of diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Contamination issues associated with the synthesis of coagulation factor concentrate
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of improved coagulation factor concentrates
      • 5.1.3.2. Significant advancements in gene therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory procedure for product approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Coagulation Factor Concentrates Market, by Type of Coagulation Factor

  • 6.1. Introduction
  • 6.2. Factor IX (FIX) concentrates
  • 6.3. Factor VII (FVII) concentrates
  • 6.4. Factor VIII (FVIII) concentrates
  • 6.5. Factor XIII (FXIII) concentrates

7. Coagulation Factor Concentrates Market, by Product Formulation

  • 7.1. Introduction
  • 7.2. Plasma-Derived Coagulation Factor Concentrates
  • 7.3. Recombinant Coagulation Factor Concentrates

8. Coagulation Factor Concentrates Market, by Application

  • 8.1. Introduction
  • 8.2. Hemophilia Treatment
  • 8.3. Surgical Procedures

9. Coagulation Factor Concentrates Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Coagulation Factor Concentrates Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Coagulation Factor Concentrates Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Coagulation Factor Concentrates Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Bio Products Laboratory Limited
  • 3. BIOGEN INC.
  • 4. Biotest AG.
  • 5. Cerus Corporation
  • 6. Emergent BioSolutions Inc.
  • 7. Kedrion S.p.A
  • 8. LFB USA
  • 9. Medscape Network
  • 10. Novo Nordisk A/S
  • 11. Octapharma USA, Inc.
  • 12. Pfizer Inc.
  • 13. Takeda Pharmaceutical Company Limited
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. COAGULATION FACTOR CONCENTRATES MARKET RESEARCH PROCESS
  • FIGURE 2. COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COAGULATION FACTOR CONCENTRATES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COAGULATION FACTOR CONCENTRATES MARKET DYNAMICS
  • TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR IX (FIX) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR VII (FVII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR VIII (FVIII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FACTOR XIII (FXIII) CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE OF COAGULATION FACTOR, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2023